Categories: News

Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2019, on Monday, March 18, 2019, after market close.

The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PDT). To participate in the call, please call 877-407-8035 (domestic) or 201-689-8035 (international) ten minutes ahead of the call and give the verbal reference “Champions Oncology.”

A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 45132, or by accessing the Investor tab of the company’s website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs. The Company’s TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions primarily in Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

Investor Contacts:

David Miller
CFO
Champions Oncology, Inc
(551) 206-8104
dmiller@championsoncology.com

Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Champions Oncology, Inc.

View source version on accesswire.com:
https://www.accesswire.com/538125/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Monday-March-18-2019

user

Recent Posts

Recognizing Outstanding Care: Healthgrades Announces 2025 Top Hospitals for Patient Experience

Healthgrades is proud to celebrate the best in patient experience DENVER, May 13, 2025 /PRNewswire/…

1 hour ago

Neural Therapeutics Announces RSU and Options Grant

Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF)…

2 hours ago

New Cold Chain Breakthrough: Invensify and GO2 Delivery Team Up to Cut Emissions, Single Use Packaging and Costs in Same-Day Pharmaceutical Delivery

Invensify and Go2 Delivery Partner to Revolutionize Sustainable Pharmacy Courier Services VIRGINIA BEACH, Va., May…

7 hours ago

Torchlight Parenting & Caregiving, a product of LifeSpeak Inc., Partners with WebMD Health Services to Expand Caregiver Support Through WebMD ONE

Integration brings Torchlight's leading caregiving solution to WebMD's wellbeing platform, enhancing support for working families…

7 hours ago

Behind the FDA’s AI Push: A Growing Class of Public Healthcare Innovators

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 13,…

7 hours ago

iotaMotion Announces First Use of Robotic-Assisted Cochlear Implant Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

ST. PAUL, Minn., May 13, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems…

7 hours ago